Training Health Personnel in Resource-Limited Settings

The critical shortage of health care professionals limits the access to care to millions of individuals in resource-limited settings. This situation requires urgent action, such as a profound transformation of the present training approach, as to (i) adapting curricula to local needs, (ii) promoting strategies to retain expert faculty staff, (iii) expose trainees to community needs during training, (iv) promote multisectoral approach to education reforms and (vi) strengthen links between the educational and health care delivery system. Western academic Institutions’€™ role is to facilitate the process. The possible strategies for assistance must be in constant and balanced partnership

 Training  Health Personnel in Resource-Limited Settings

                                          

                by Francesco Castelli*  and  Marianna Bettinzoli**

* Chair of Infectious Diseases, University of Brescia, Italy

**PhD trainee in “€œMethodology and Appropriate Techniques for International Development Cooperation”€, University of Brescia, Italy

 

Background

The right of millions of people around the world to have access to care is jeopardized by the shortage of health care personnel. Only in the African continent, the global burden of diseases is estimated to be as high as 27% of the world’€™s total despite only 12% of the world population live here. The problem is even more critical because the continent only have 3,5% of the total healthcare workforce 1. This shortage is critical, as recognized by Word Health Organization (WHO) in its 2006 annual report requesting urgent interventions. The shortage is even more dramatic if one considers that over 75% of physicians in Sub-Saharan Africa live and work in the urban setting, leaving the rural areas nearly devoid of care providers 2.

The reasons for this shortage of health care professionals where they are more needed are various:

First, in low-income countries, the training of health professionals is quantitatively limited 3. This limited capability is due to scarce funding, poor infrastructure, the highly qualified teachers often search for more remunerative and attractive jobs abroad.

Second, after graduation, a great proportion of health professionals declares its willingness to migrate 4. Among the identified reasons for migration, in decreasing order, are 2: (i) better remuneration, (ii) safer environment, (iii) living conditions, (iv) lack of facilities and  (v) the absence of future. Understanding the reasons for migration is crucial in order to define and to put into practice strategies to limit brain drain 5. Other Authors estimate that other factors, apart from financial incentives, including working and living conditions, social and political insecurity could play a even more important role in the migration decision 6.  The Global Code of Practice on the International Recruitment of Health Personnel has been recently launched by WHO,  requesting all member States to take action to facilitate retention of health personnel in those areas where they are most needed 7.

Third, the social and economic prestige of the health professions is better exploited in the urban setting 8. One possibility to contrast this phenomenon is context-appropriate medical training. In fact, exposing medical students to problem-based learning approach in the rural settings areas may influence their attitude and willingness to work in rural remote areas once graduated 9.

The challenge of health education in resource poor countries

Many strategies have been put forward to combat global health worker shortages, with conflicting results.

Task shifting, the progressive inclusion of tasks, traditionally ascribed to the medical or surgical profession, among the job descriptions of lower level health care professionals, has been advocated by many international Agencies and adopted by many developing countries 10. Training of mid-level personnel has also been implemented in same situations and global standardization of curricula would be desirable to share expertise and compare training experiences 11. Task-shifting and mid-level health professionals are not to be considered a makeshift solution in resource-poor settings but instead as true strategies.

To retain the health professionals in remote areas, offering specific benefits (i.e. housing, etc.) that might elevate their social and economic status might be influence the willingness to migrate 12. On the contrary, the widespread use of per diems for in-job training has motivated health professionals to actively search for continuous training remunerative activities leaving their clinical duties, an attitude referred to as “€œperdiemitis”€ 13. Furthermore, reinforcing the social accountability and ethical commitment of medical trainees to engage himself to the underserved community appears crucial.

Finally, the careful planning of training needs for health care professionals (both quantitatively and quantitatively) should involve different sectors at the governmental level and particularly the education and the health sectors 14.

What western education institutes may contribute?

Literature on the medical education needs of resource-poor countries is scanty and, unfortunately, it has been mostly published by Authors working in western institutions. Only quite recently, the academic leaders from the southern countries have raised their voice about the problems and have proposed solutions 15.

When putting in place a training or research partnership between academic institutions from the North and the South, many possible mistakes have to be carefully avoided when  partnering for medical education in southern countries. These are: i) curricula are often  western-centered, ii) the social and cultural contexts are not considered, iii) tendency to create specialists instead of public health expert without attention to multidisciplinary approach, iv) unbalance between the teaching staff from the north and the south, with little incentives for the latter, v) prolonged training periods of time spent in affluent countries , vi) use of sophisticated training material vii) the local public health system and economic authorities are poorly involved.

The following are among some additional possible solutions to increase quality and quantity of medical education in the south through a possible help by western academic institution.

Long distance internet-based teaching resources. They are attractive and have the advantage to limit travels, vacancies and costs. Positive experiences have been reported 16. The main difficult is the adaptation to the recipients’€™ settings in terms of social, cultural, legal, economic and, sometimes, religious context. Furthermore, on-line training requires access to electronic facilities and internet competencies 17.

Assistance in quality control procedures, external evaluation and accreditation. The maintenance of high quality of education is essential to gain credibility at the national and international levels 18.

Promoting independent research activity in developing countries.  To have a high quality teaching and training, promoting research capability is crucial. The creation of a independent research career path for physicians from resource-limited countries is needed 19.

Concluding remarks

The critical shortage of health care professionals limits the access to care to millions of individuals, especially where the need is higher. This is mainly caused by poor training capabilities of academic institutions in developing countries, the attitude of health care personnel to migrate to more affluent western countries and the unwillingness of local doctors to work in the most in need rural areas. This situation requires urgent action, such as a profound transformation of the present training approach, as to (i) adapting curricula to local needs, (ii) promoting strategies to retain expert faculty staff, (iii) expose trainees to community needs during training, (iv) promote multisectoral approach to education reforms and (vi) strengthen links between the educational and health care delivery system 19. Western academic Institutions’€™ role is to facilitate the process. The possible strategies for assistance must be in constant and balanced partnership.

References

1) WHO. Core Health Indicators 2008, World Health Organization, Geneva, 2008 http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf

2) WHO. World Health Report 2006. Working together for Health. World Health Organization, Geneva, 2006

3) Mullan F, Frehywot S, Omaswa F et al. Medical schools in sub-Saharan Africa. Lancet, 2011 Mar 26;377(9771):1113-21

4) Chen C, Buch E., Wassermann T et al. A survey of Sub-Saharan African medical schools. Human Resources for Health, 2012, 10:4 http://www.human-resources-health.com/content/10/1/4

5) Oyeyemi AY, Oyeyemi AL, Maduagwu SM et al. Professional satisfaction and desire to emigrate among Nigerian physiotherapists. Physiotherapy Canada, 2012; 64: 225-232

6) Vujicic M, Zurn P, Diallo K et al. The role of wages in the migration of health care professionals from developing countries. Human Resources for Health 2004, 2, 3 http://www.human-resources-health.com/content/2/1/3

7) Mills EJ, Kanters S, Hagopian A et al. The financial cost of doctors emicrating from Sub-saharian Africa: human capital analysis. British Medical Journal, 2011; 343:d7031 doi:10.1136/bmjd7031

8) Burch VC, McKinley D, van Wyk J et al. Career intentions of medical students trained in six sub-saharan African countries. Educ Health (Abingdon), 2011; 24: 614

9) Kaye DK, Mwanika A, Sewankambo N. Influence of training experience of Makerere University medical and nursing graduates on willingness and competence to work in rural health facilities. Rural and Remote Health, 2010 http://www.rrh.org.au

10) Nelson R. Combating global health worker shortages: task shifting and sharing may provide one solution. Am J Nurs, 2012; 112: 17-8

11) Brown A, Cometto G, Cumbi A et al. Exchange of the Global Health Workforce Alliance. Rev Peru Med Exp Salud Publica, 2011; 28: 308-15

12) Hagopian A, Ofosu A, Fatusi A et al. The flight of physicians from West Africa: views from African physicians and implication for policy. Social Science and Medicine, 2005; 61: 1750-60

13) Ridde V. Per diems undermine health interventions, systems and research in Africa: burying our heads in the sand. Trop Med Int Health. 2010 Jul 28. doi: 10.1111/j.1365-3156.2010.02607.x

14) Celletti F, Reynolds TA, Wright A et al. Educating a new generation of doctors to improve the health of populations in low- and middle-income countries. PLOS Medicine 2011  http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001108

15) Kiguli-Malwadde, Kijjambu S, Kiguli S et al. Problem Based Learning, curriculum development and change process at Faculty of Medicine, Makerere University, Uganda. African Health Sciences 2006; 6: 127-130

16) Chung MH, Severynen AO, Hals MP et al. Offering an American graduate medical HIC course to health care workers in resource-linited settings via the internet. PLOS One, 2012; 7: e52663. doi:10.1371/journal.pone.0052663

17) Mohammed E, Andargie G, Meseret S, Girma E. Knowledge and utilization of computer among health workers in Addis Ababa Hospitals, Ethiopia: computer literacy in the health sector. BMC Research Notes, 2013; 6: 106 http://www.biomedcentral.com/1756-0500/6/106

18) Galakunde M, Opio K, Nakasujja N et al. Accreditation in a sub-Saharan Medical School: a case study at Makerere University. BMC Medical Education 2013; 13/73 http://www.biomedcentral.com/1472-6920/13/73

19) Manabe YC, Katabira E, Brough R et al. Developing independent investigators for clinical research relevant for Africa. Health Research Policy and Systems, 2011, 9:44 http://www.health-policy-systems.com/content/9/1/44

 

*Francesco Castelli, MD, FRCP (London), FFTM RCPS (Glasgow), is Professor of Medicine (Infectious Diseases) and Director of the University Division of Infectious and Tropical Medicine at the Università  degli Studi di Brescia (Italy). He is also Director of the Specialty School in Infectious Diseases at the same University. He serves as the Vice-President of the Italian Society of Tropical Medicine (SIMET) and is Member of the Board of Directors of the International Society of Travel Medicine (ISTM). He is site Director of the Brescia Geosentinel site and of the WHO Collaborating Center for the implementation of TB/HIV collaborative activities. He is past-President of the Italian NGO Medicus Mundi Italy. His major fields of scientific interest are tropical diseases, migration medicine, travel-related and imported infections and HIV/AIDS both in industrialized and developing Countries. He has published more than 180 papers on peer-reviewed journals and more than 100 chapters of Books and Manuals.

**Marianna Bettinzoli, MD. She is in PhD training in “€œMetodology and Appropiate Techniques for International Development Coopoeration”€ at the University of Brescia. Her major fields of scientific interest are global health, migration medicine and public health.

News Link n. 66

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 66

First malaria vaccine in 2015?  

We Read the New World Bank Group Strategy, So You Don’t Have To

World Bank leadership in transition

TPP Leaders: Negotiations “On Track,” Pushing for 2013 Finish

At the Committee on World Food Security, despite acknowledging the evidence, the US and the EU refuse to act to eliminate harmful biofuels

Netherlands leads new push for climate-smart agriculture

FAO: Modernisation or Irrelevance  

FAO will cooperate with La Via Campesina, the largest movement of small-scale food producers in the world

UNICEF: Why we’re launching a new climate change campaign

Annual Meetings: Kim, Lagarde Talk Climate Change and Growth  

Green Climate Fund meets amid cash problems

African countries getting ready for Green Climate Fund  

Right To Benefits Of Science: Human Rights Meet IP Rights 

Perplexed About International Policy On GR, TK and TCEs? Here’s A Book 

JLME Issue on Institutional Corruption and the Pharmaceutical Industry  

Yunus sets deadline for an end to poverty

EU Development Goals Left In The Shadow Of Trade Policy

48 European civil society organisations endorse EU Manifesto on Global Health 

Universal health coverage, real or selective? Time for global health advocates to unite 

Health Equity and Financial Protection in Asia (live from Yogyakarta, Indonesia) 

(Some) work makes us sick: Some reflections on the International Day for Decent Work  

Polio eradication and the lens of established thought  

Transport and foreign aid: Big connection

Joris Voorhoeve appointed Chair of Oxfam International  

 

 

News Link n. 65

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 65

WHAT DOES THE SHUTDOWN MEAN FOR PATENTS?

How a Government Shut Down Would Affect the United Nations  

I Repubblicani contro la riforma di Obama

LA GIORNATA MONDIALE DELL’ALIMENTAZIONE  (16 ottobre 2013)

Nagoya Protocol Halfway To Required Number Of Accessions

Global Knowledge platform launched to galvanize women’s economic empowerment

EU countries urged to invest in reducing health inequalities

Food and drink firms urged to crack down on sugar ‘land grabs’

Is The Global Fund Really Worth $5 Billion?

Africa’s Mineral Wealth Can Be a Springboard for Development

5 ways for NGOs to get smarter about private-sector engagement

Making All Voices Count – promising new initiative (and source of funding) 

Donor funding for HIV and AIDS grew marginally in 2012

Infographic: Carbon Markets of the World

CUAMM, Milano 16 novembre 2013: Prima le mamme e I bambini

WIPO Annual Assembly Breaks Down; Extraordinary Meeting Eyed For December 

Health rights in the post-2015 development agenda: including non-nationals

Push to tackle corruption in post-2015 agenda 

Hospital payment systems based on diagnosis-related groups: experiences in low- and middle-income countries

Towards a framework convention on global health

Governments in Trans-Pacific trade deal urged to reject political trade-offs harmful to access to medicines 

Positive signs for malaria vaccine based on GM parasite

 

What’s in the HIV Drug Pipeline? Advocating for a Healthier Innovation System

The storyline of patent protection incentivizing the invention of new drugs has come under scrutiny. In the field of HIV, a closer look at the drugs in the pipeline reveals that rather than being new chemical entities, the majority of the most salient pipeline drugs represent incremental changes to existing drugs. These incremental innovations, which often result from routine practice or obvious adjustments, are not breakthrough inventions. Yet the market monopolies awarded to these drug companies can pose barriers to the ability of patients and governments to access medicines. In this article, we flesh out this story of the HIV antiviral pipeline in order to showcase the drawbacks of the current patent system and provide a prescription for a healthier innovation regime

 
What’s in the HIV Drug Pipeline? Advocating for a Healthier Innovation System

                 priti-thumbnail

       by   Jimmy Pan* and Priti Radhakrishnan**

 Initiative for Medicines, Access & Knowledge (I-MAK.org)

 

THE HIV DRUG PIPELINE

ANTI-RETROVIRAL THERAPY (ART)

Background

Why are new anti-retrovirals needed if so many already exist? First, drugs that employ new biochemical pathways to combat the HIV virus may be more efficacious than existing drugs. These new pathway drugs may also be used in combination with existing drugs in order to create a multi-pronged attack that is less likely to succumb to viral resistance. Secondly, while prices of first-line regimens have fallen due to increased generic production worldwide, many patients become resistant to these treatments. These patients need either new drugs or new combinations. Third, updated versions of existing treatments may provide additional benefits, e.g. less toxicity.

When the public imagines drug innovation, it typically conjures up the laboratory researcher discovering new compounds with new, unexpected mechanisms of actions. The question that we sought to resolve was whether this image reflects reality, e.g. if the HIV pipeline of medicines is comprised of new chemical entities, or whether the HIV drug pipeline is a collection of incremental changes to existing compounds.

Incremental Innovation

Incremental innovation is prevalent in medicine patenting, including the patenting of new forms of known compounds and combinations of older compounds. New forms of known compounds include the creation of derivative compounds, salts, polymorphs, prodrugs, formulations etc. Combinations are created when two or more known drugs are combined into a single treatment. Often, incremental innovations demonstrate a benefit that is not therapeutic in nature, such as increased stability of a drug product. Stabilization involves improving the stability of the drug in various environmental conditions, such as improving heat stability or shelf-life.

The unifying theme between the different types of incremental innovation is their routine nature: they are usually generated via commonly practiced pharmaceutical techniques. For example, the lab processes employed to create salts of known compounds are regular practice and are well known to the pharmaceutical community. That is not to posit that these drugs have no worth, but we do propose that this sort of routine practice does not warrant a new twenty-year term of market exclusivity, because it does not result from the type of inventiveness that warrants such a monopoly.

Countries are beginning to recognize the routine nature of incremental innovation. As an example, India has rejected combinations of known HIV drugs, as well as the heat-stabilized version of ritonavir/lopinavir. Brazil also recently rejected a patent application for a salt derivative of the already-known drug tenofovir.

PIPELINE SUMMARY

Ideally, the patent system ought to provide sufficient incentive to create new chemical entities. Yet, an analysis of the pipeline for upcoming HIV drugs reveals that the patent system is not meeting this promise.

We analyzed the eleven upcoming HIV drugs in the pipeline (The Roadmap: The HIV Drug Pipeline and its Patents), which hold the most relevance for low- and middle-income countries. These drugs were selected based on a review of the latest available information from scientific and public health experts. Our scientific and legal team compared these pipeline drugs against existing drugs and analyzed the quality and strength of these patents.

Eight of the eleven drugs analyzed were found not to be new chemical entities with new mechanisms of action. Instead, many of these pipeline drugs were new forms of known substances or combinations.

To provide a few key examples from our findings:

CMX157 and tenofovir alafenamide fumarate (TAF) are merely new forms of the existing HIV drug tenofovir, which are likely be found to be obvious or non-inventive given existing pharmaceutical practices.

Complera (tenofovir disoproxil fumarate +emtricitabine + rilpivirine) and Stribild (tenofovir disoproxil fumarate +emtricitabine + elvitegravir + cobicistat)  are both merely combinations of various existing HIV drugs. These combinations offer no increase in therapeutic efficacy over the individual drug components.

Cobicistat is merely an analog of the HIV drug ritonavir (which comes off patent in the near future) with no clinical benefit offered over ritonavir.

Etravirine is structurally similar to and is a derivative of known compounds already disclosed in the prior art.

Other examples can be found in The Roadmap: The HIV Drug Pipeline and its Patents.

PROBLEM DESCRIPTION

Our purpose in assessing the HIV drug pipeline was to highlight one of the issues central to the patent system: that patents on incremental innovation can prevent access to needed treatment.

First, the ability to obtain patents on incremental, non-innovative changes may be detrimental to innovation of new therapies, rather than positive. It is well documented that companies regularly file incremental applications in order to extend the life of their existing patents and lengthen the effective patent term. This allows companies to retain market exclusivity without requiring them to innovate truly new medicines after their existing drug patents expire. Empirical evidence reveals that the rate of innovation has indeed started to slow down.

This market exclusivity permits companies to keep prices out of reach. For example, Ukraine is currently paying 10.13 times the lowest generic price for the pipeline HIV drug raltegravir, $6843 per person per year (pppy) versus $675 for the generic. Similarly, Argentina is paying 10.86 times the lowest generic price for the first-line drug atazanavir, $2912 pppy versus $268 pppy. These prices make it difficult or infeasible for governments to procure treatment for patients in low- and middle-income countries.

Second, the use of incremental patents as “€œblocking patents” can prevent the development of new technologies. In these cases, generic ART manufacturers are denied the ability to combine existing drugs into new combination therapies. This inability to produce new combinations generically is exacerbated by the refusal of many originators to voluntarily license their drugs to be used in combination therapies.

LEGAL SUMMARY

Another factor to consider is whether and where these pipeline drugs are being patented. We know from our patent searches that patent applications have been filed for all pipeline drugs analyzed for The Roadmap. Our preliminary patent landscaping in middle-income countries shows that patents on these compounds have been filed extensively in Argentina, Brazil and Ukraine, among others. Whether these applications are granted or denied depends on the patent regime of the individual country.

The law in the US, EU, and many other jurisdictions are favorable to patents on new forms of known substances, new uses and combinations. In these jurisdictions, several of the patent applications on these eight drugs have already been granted.

The negative impact of a granted patent in these countries might not be felt immediately (as a number of these drugs are still awaiting regulatory approval), but several implications are nevertheless clear. Most immediately, the newly granted patents may be used in litigation as blocking patents to block entry of generic combination therapies or other modified, similar forms of known drugs. By blocking entry of generic competition, the patentees retain the market power to keep drug price high, even after the patents for the older compounds expire.

In contrast, the patent policy in countries such as India, Argentina, and the Philippines is to impose stricter standards for obtaining patents for incremental innovation.

In India, for example, applications for new forms of known compounds must demonstrate increased efficacy in order to qualify for a patent. The 2013 Indian Supreme Court judgment Novartis v Union of India clarified that the law requires a demonstration of increased therapeutic efficacy. This means that pharmaceuticals may obtain patents on incremental changes if and only if they can demonstrate that the change provides real improvement to patients. This “€œincreased therapeutic efficacy”€ requirement requires applicants to submit scientific data demonstrating improvement in patient health; in US/EU-like patent regimes, applicants are not required to demonstrate an improvement in therapeutic efficacy, but merely that there is some unexpected advantage, which does not have to be therapeutic, and is a much lower bar. Under India’€™s legal standard, our review indicates that these eight pipeline ARVs should not be granted.

There are many benefits to the approach India and other countries are adopting. The immediate impact is to free manufacturers to create new combination therapies, variations on existing drugs, or generic versions of off-patent medicines. This benefit cannot be understated for patients who have developed resistance against existing first- and second-line HIV therapies.

This approach also ensures long-term sustainability for the patent system, where patent rights are given only to genuinely innovative creations, as opposed to permitting the system to bloat with a surfeit of marginally innovative patents.

FIXING THE PROBLEM

PATENT OFFICE

Patent examiners play an important role on access to essential medicines, especially for the upcoming HIV pipeline drugs.

In most countries, examiners should strongly consider rejecting these patents for lack of inventive step since many of the techniques employed are routine and obvious to those skilled in pharmaceutical practice.

In offices that operate under the India/Argentina/Philippines patentability standard, examiners should evaluate these pipeline drug applications for what they are: secondary, incremental improvements to known drugs, rather than genuinely new medicines.

HEALTH MINISTRIES

Each health ministry, in order to improve domestic public health, should increase monitoring efforts to understand the impact of the country’€™s patent system on treatment access. For example, our own analysis indicates that patents on pipeline ARVs may prevent generic production and make drugs unaffordable for government procurement programs.

A health ministry may observe, for example, that tenofovir alafenamide fumarate (TAF) is granted a patent in its jurisdiction. It can then note that the TAF patent would have been rejected under an India/Argentina/Philippines-like patent regime, or if the examiner had employed stricter inventive step standards. If the patent has been improperly granted (e.g. TAF in India), the health ministry should intervene by law where permitted, e.g. by filing a Section 64 revocation action in India.

The ministry can concomitantly monitor the increased cost to government procurement that ensues from restricting generic production of TAF, and keep track of the number of patients which are subsequently denied access to TAF. Only by keeping such tabulation on essential-medicine patent grants can a national health ministry make a meaningful assessment of the public health impact of its own patent laws. Health ministries can utilize this evidence to demonstrate the need for national patent reform in the interest of improving treatment access. They can push for stricter patentability standards which require new forms of known substances to improve therapeutic efficacy, or simply standards which exclude routine derivatives wholesale. They can also flag to the patent offices that inventiveness should be examined more closely, especially for pharmaceutical development.

PATENT REFORM

The majority of countries lack higher patent requirements for incremental improvements to known drugs. This limits the ability of patent examiners to exclude those applications which are not truly innovative. The inability to reject incremental patents can be observed, for instance, by noting the expansive patent clusters (over a hundred patents in the U.S.) surrounding the HIV drug Kaletra.

To provide those tools to examiners, legislators should amend patent regimes to provide examiners with the ability to screen out incremental patents, particularly for medicinal compounds essential to health -€“ requiring applicants to make a showing of therapeutic improvement. Some countries have taken steps to amend their laws in this fashion. Brazil, for example, has introduced proposals to adopt patent requirements similar to India’€™s higher requirements for new uses of known compounds.

If the first step towards strengthened patent examination is higher standards for patentability, then the second is third party participation in patent hearings. Several countries allow for this form of “€œcitizen review,”€ including the Australia, Brazil, Argentina, Indonesia, Vietnam, Pakistan, India, Thailand, and the Philippines. In these countries, third parties are permitted to submit scientific evidence to the patent examiners prior to the granting of the patent, rather than attempt to invalidate the patent after the grant. Some of these countries allow third parties to participate in the examination of the patent, while others, like India, also allow a hearing prior to the grant. Pre-grant citizen review helps set out evidence for rigorous patent examination that the examiner may not otherwise be exposed to. Citizen review in India has helped examiners to make more informed decisions about the ingenuity of the claimed products, leading to the rejection of several non-inventive patent applications. Yet the US and EU continue to restrict third party participation worldwide by introducing provisions into their bilateral trade agreements with other countries, which prohibit these procedures. Countries should resist this external pressure, and adopt the ability to have pre-grant citizen review.

CONCLUSION

Our analysis of pipeline HIV drugs reveals that the next wave of drugs is the result of incremental changes which are routine practice. Eight of eleven pipeline drugs should be denied patents to ensure that the next generation of HIV medicines reaches patients who need them and that the integrity of the patent system remains intact.

In this light, we hope that patent offices and legislators worldwide can develop evidence-based reforms to the patent regime. If countries set higher standards for incremental innovation patenting, and permit citizen or third-party review of patents before and after examination, then we will likely see increased generic competition in the ART market, new combination therapies, and lower ART prices. In the longer term, higher inventiveness standards will help clear the patent thicket to allow new products to develop, and push industry towards genuine innovations. The HIV pipeline illustrates why patent reform is necessary in order to improve treatment availability for patients across the world. Citizens, examiners, and health officials alike should resist the patenting of the derivative pipeline drugs, so People Living with HIV (PLHIV) have access to all treatments.

For further information, please visit The Roadmap: The HIV Drug Pipeline and its Patents.

—————————————————————

*Jimmy Pan is an staff attorney and public health professional at I-MAK. Prior to his transition into law, he contributed to HIV research as a laboratory scientist. All I-MAK research is available at www.i-mak.org.

**Priti Radhakrishnan is Co-Founder and Director of Treatment Access of Initiative for Medicines, Access & Knowledge (I-MAK), a team of lawyers and scientists increasing access to affordable medicines by making sure the patent system works. Prior to founding I-MAK, she served as the Senior Project Officer of the Lawyers Collective HIV/AIDS Unit in India. Most recently, Priti was awarded the National South Asian Bar Association’s Public Interest Achievement Award and was named to the Good 100, a selection of the 100 most innovative individuals changing the world.

Intervista: Jean-Louis Aillon

 

Intervista

 Jean-Louis Aillon

Vicepresidente Movimento per la Decrescita Felice e referente del gruppo tematico “€œDecrescita e Salute”€

 

Jean-Louis Aillon, 28 anni, medico, specializzando in psicoterapia dinamica adleriana. E'ˆ vicepresidente del Movimento per la Decrescita Felice e referente del gruppo tematico "€œDecrescita e Salute"€. E'ˆ stato fondatore e presidente del circolo della Decrescita Felice di Torino e del Comitato Rifiuti Zero Valle d'€™Aosta. A livello di ricerca, si interessa principalmente dei temi inerenti la decrescita, la salute (in particolare nell'€™ambito dell'€™etnopsichiatria critica e della psichiatria culturale) e i giovani.

 

Background information

Il Movimento per la Decrescita Felice (MDF) è un movimento italiano nato e cresciuto informalmente dall'inizio degli anni 2000 sui temi della demitizzazione dello sviluppo fine a se stesso, e successivamente sfociato in un'associazione fondata da Maurizio Pallante, esperto di risparmio energetico. Il movimento parte dal presupposto che la correlazione tra crescita economica e benessere non sia necessariamente positiva, ma che esistano situazioni frequenti in cui ad un aumento del Prodotto interno lordo (PIL) si riscontra una diminuzione della qualità  della vita. 
Il 29 Luglio 2013, il gruppo tematico "€œDecrescita e Salute"€ di MDF è stato convocato per un'€™audizione alla Camera dei Deputati nel corso dell'€™indagine conoscitiva dal titolo "€œLa sfida della tutela della salute tra nuove esigenze del sistema sanitario e obiettivi di finanza pubblica"€, portata avanti dalle Commissioni riunite V (Bilancio, tesoro e programmazione) e XII (Affari sociali).
E'€™ intervenuto in videoconferenza Skype Jean-Louis Aillon, vicepresidente di MDF e referente del gruppo tematico Decrescita e Salute. Egli ha spiegato come nell'€™attuale scenario, chiusi fra la morsa della crisi economica da una parte e il vincolo del pareggio di bilancio dall'€™altra, declinando la visione della decrescita nell'€™ambito della sanità  si potrebbe uscire dalla terribile "€œimpasse"€ in cui ci troviamo. Si tratta di invertire l'€™attuale rotta, di costruire un nuovo modello di salute, di cura e quindi di sanità. Al centro dovrà  esserci la salute, il pieno benessere fisico, psichico e sociale degli esseri umani, piuttosto che il profitto delle multinazionali del farmaco e degli "€œstakeholder"€ sanitari, la qualità  al posto  della quantità. Ciò significa investire risorse, in primis, nella promozione della salute e nella prevenzione delle malattie agendo in via prioritaria sui determinanti di salute a livello della società  (ambiente, stili di vita, condizioni socio-economiche e culturali), coinvolgendo i cittadini e le comunità  in questo processo,  favorendo la resilienza della comunità  stesse e del sistema sanitario, decentralizzando le cure a livello del territorio. Parola d'€™ordine: "€œmeno e meglio"€, ovvero efficienza ed appropriatezza delle cure, combattendo il consumismo farmaceutico e il cosiddetto "€œdisease mongering"€, ovvero la commercializzazione delle malattie (Decrescita e salute. Aillon.audizione commissione affari sociali.29.07.13).

Nel merito, il Dr. Aillon è stato intervistato da GESPAM:

GESPAM:  Dr. Aillon, può dirci qualcosa circa l’€™origine, la struttura e l’€™operatività  del Gruppo “€œDecrescita e Salute”€ di cui è referente?

Jean-Louis Aillon: Il gruppo nasce in seguito ad un percorso di riflessione su questi temi che ho inizialmente intrapreso quando ero studente in medicina, nel 2009. Organizzammo allora, con il collettivo degli studenti “€œmedici senza bandiere”€, una conferenza dal titolo “€œDecrescita in medicina”€, dove intervenni insieme a Maurizio Pallante. In seguito vi sono stati altri eventi e sempre più persone mi hanno contattato per discutere e riflettere assieme su questi tematiche, fino a quando, nel 2011, abbiamo deciso di costituire ufficialmente il gruppo.

Il gruppo tematico “€œDecrescita e Salute”€ fa parte del Movimento per la Decrescita Felice (MDF) ed è costituito attualmente da un gruppo eterogeneo di persone (medici, psicologi, operatori socio-sanitari e cittadini interessati),  provenienti da tutta Italia e facenti perlopiù parte di MDF (ma non solo). Lavoriamo prevalentemente via web tramite una mailing list e, saltuariamente, ci troviamo di persona. Il gruppo è aperto: chiunque vi può partecipare e proporre una riflessione o un progetto.

GESPAM: Maurizio Pallante ha detto che “€œLa decrescita è il capovolgimento dell’€™assunto che la crescita illimitata sia il fine delle attività  economiche e produttive”€. Quali implicazioni per la salute?

Jean-Louis Aillon: L’€™implicazione maggiore è, forse, il porsi la seguente domanda: la crescita economica senza limiti e fine a se stessa è la chiave di volta per ottenere “€œsalute per tutti”€ (come ci raccontano tutti i media), oppure costituisce essa stessa uno dei principali impedimenti per raggiungere questo obiettivo?

Pensate, per esempio, al seguente paradosso: se stiamo fermi con l’€™automobile in mezzo al traffico, se mangiamo cibi contaminati con la diossina, se lavoriamo stressati dieci ore al giorno, ci ammaliamo maggiormente e consumiamo più medicine. Stiamo male ma il prodotto interno lordo cresce ed alcuni economisti direbbero che aumenta “€œil nostro benessere”€! Parlare di decrescita nell’€™ambito della salute implica, quindi, il mettere in dubbio il dogma della crescita (“€œpiù crescita=più benessere=più salute”€) e rimettere al centro la salute.

GESPAM: In termini di salute, e non solo, quale fine ultimo per la decrescita così intesa?

Jean-Louis Aillon: Il fine ultimo è quello di mirare a garantire la massima salute possibile (intesa come pieno benessere fisico, psicologico e sociale) a tutti gli esseri umani di oggi e di domani, svincolando il Sistema Socio-sanitario dalle pressioni produttivistiche del sistema della crescita (dove spesso i pazienti, invece di essere il fine ultimo, rischiano di diventare un ingranaggio della “€œmegamacchina”€, un mezzo per garantire profitto ai grandi stake-holders del settore), agendo a 360 gradi nella società  sui vari determinanti di salute.

Decrescita e salute, significa però anche invertire il “€œtimone culturale”€ della crescita, ovvero svincolare la scienza biomedica dalle influenze generate, nel corso dei secoli, da un sistema economico basato esclusivamente sulla crescita del pil (e non sul perseguimento del ben vivere dell’€™umanità ); affrancarla da una visione miope della scienza e del progresso (€œmaterialista, meccanicistica, biecamente riduzionista e non olistica) la quale ha fatto dell’€™uomo un oggetto di studio come gli altri, trascurandone le varie dimensioni essenziali (non materiali), la sua unitarietà  e la sua complessità  (soprattutto a livello emotivo). La decrescita, come in economia, si propone di riorientare la medicina secondo un carattere prettamente qualitativo (e non quantitativo), riportando l’€™unicità della persona al centro del processo medico e promuovendo tutte quelle pratiche che mirino al reale benessere psico-fisico e sociale dell’€™essere umano, inteso nella sua globalità  (abbandonando tutte quelle pratiche che invece perseguono interessi diversi). Inoltre in antitesi con l’€™approccio scientifico/positivistico “€œla medicina della decrescita”€ non contrappone l’€™uomo alla natura attraverso una logica di dominio e di controllo assoluto, ma vede l’€™uomo come parte della natura stessa, in armonia con essa e promuove un concetto di salute che non può prescindere dalla cura e dal rispetto dell’€™ambiente circostante. Ci richiede di “€œdecolonizzare il nostro immaginario”€ (sia per gli operatori della salute, che per tutti noi potenziali pazienti) dall’€™idea di onnipotenza insista nella medicina e nella società  occidentale odierna, riappropriandoci del concetto di limite per cominciare a guardare al mondo con occhi diversi.

GESPAM: Determinanti della salute e pilastri per l’€™azione: può precisare?

Jean-Louis Aillon: Maurizio Pallante ritiene fondamentale, per mettere in pratica la decrescita, agire su quelle che definisce le tre gambe di uno sgabello (tecnologie, stili di vita e politica) che sostengono il pianale del nuovo paradigma culturale. Un simile esempio potrebbe esser fatto per la salute con l’€™immagine di quattro pilastri: prevenzione, partecipazione, riorganizzazione del Servizio Sanitario e nuovo modello di salute/cura.

La questione dei determinanti di salute – legata alla prevenzione primaria e alla promozione della salute –  è fondamentale e consiste nel primo pilastro: la colonna portante del nuovo modello a cui vorremmo arrivare. Le ricerche indicano che il nostro stato di salute dipende in misura maggiore dalle nostre condizioni socio-economiche, ambientali e culturali, che dal  Servizio Sanitario 1-3.  Una società  basata su una crescita economica senza limiti e regole (il moderno neoliberismo) centralizza ed investe la maggior parte delle risorse dedicate alla salute nel Sistema Sanitario (sotto la pressione dei vari stakeholder), mentre investe poco o nulla sulla prevenzione delle malattie e sulla promozione della salute (che purtroppo non “€œfruttano”€ molto). Inoltre, i meccanismi alla base della crescita economica (indiscriminato sfruttamento del capitale umano e naturale) portano sostanzialmente al peggioramento dei determinanti ambientali e delle condizioni socio-economiche (crescenti ineguaglianze) per la gran parte della popolazione. Per fare un esempio, è come se, nevroticamente, cercassimo di togliere dell’€™acqua da un secchio con una mano e con l’€™altra aprissimo il rubinetto!

Penso sia quindi fondamentale dare priorità  alla riparazione del rubinetto, alla prevenzione primaria e alla promozione della salute, agendo in via prioritaria sui determinanti di salute adottando una prospettiva multisettoriale e transdisciplinare che coinvolga tutti i settori e gli aspetti dello sviluppo nazionale e della comunità legati alla salute 4-5.  Si tratta, quindi, di tutelare l’€™ambiente, promuovere maggiore equità  sociale ed una cultura attraverso la quale possano delinearsi stili di vita più sani e sostenibili..

Vi sono però anche degli altri pilastri, non meno importanti, che sono alla base del nostro pensiero e senza i quali il nostro intero edificio sarebbe destinato a crollare. Il secondo pilastro, fondamentale, è la promozione della partecipazione e del coinvolgimento dei cittadini e delle comunità  nelle scelte politiche inerenti la salute, nell’€™ottica di una gestione collettiva del bene comune rappresentato dal Sistema Sanitario Nazionale (SSN) 6.

Vi è poi la riorganizzazione del Servizio Sanitario Nazionale secondo una logica di efficienza e appropriatezza (“€œmeno e meglio”€), una sua decentralizzazione nell’€™ottica di valorizzare sempre più la medicina di comunità 7,  promuovendo inoltre una integrazione con il mondo delle medicine alternative e complementari (agendo in un’€™ottica di rete, soprattutto per quanto riguarda la promozione della salute, prima ancora che nel versante della cura) 8-9.

Il quarto ed ultimo pilastro è, infine, lo sviluppo di un nuovo modello di salute, cura e sanità  che ponga al centro la persona vista in una prospettiva olistica (entità  bio-psico-socio-spirituale in continua relazione con il circostante ambiente fisico e relazionale), la relazione fra gli operatori socio-sanitari ed il paziente, e che cerchi di applicare il necessario riduzionismo senza rinunciare a contemplare la complessità  (e quindi la soggettività) nella sua totalità,  riconoscendo i limiti della medicina stessa e della scienza in generale.

Questi sono, in sintesi, i fondamenti di un nuovo modello di sanità. Pilastri che necessitano di un nuovo paradigma culturale, del pianale della decrescita, per poter diventare solide basi su cui edificare un futuro migliore per la nostra salute.

GESPAM: Dalla enunciazione alla pratica: cosa proponete?

Jean-Louis Aillon: Agire con tutti i mezzi a disposizione, nelle nostre possibilità, a due livelli. Dal punto di vista individuale come cittadini è fondamentale promuovere certe idee ed una particolare visione del mondo e della salute, anche partendo da piccoli progetti concreti o dalle nostre scelte quotidiane. Prima di parlare di medicina di comunità, serve infatti che vi sia una comunità!  In secondo luogo è importante impegnarsi politicamente (agli alti come ai bassi livelli) perchè queste idee possano trasformarsi un giorno in politiche concrete.

Da questo punto di vista penso che grande importanza possano avere le associazioni che si occupano di salute. Esse potrebbero essere il collante fra lo Stato (e quindi il Sistema Sanitario Nazionale) e le comunità.

GESPAM: Dr. Aillon, il vostro “€œProgetto medici per la decrescita”€ è imperniato su 10 principi: può riferirci?

Jean-Louis Aillon:  Si tratta fondamentalmente di 10 principi (vedasi Decrescita e salute. Aillon.audizione commissione affari sociali.29.07.13) che riassumono molte delle questioni sopracitate e che ogni medico può impegnarsi a rispettare dichiarandosi un “€œmedico per la decrescita”€. L’€™obiettivo del progetto è duplice: da una parte favorire i cittadini nella scelta di un medico che abbia una certa visione della medicina (e del mondo), dall’€™altra favorire la diffusione da parte del medico delle idee inerenti la tematica “€œdecrescita e salute”€. Stiamo, inoltre, lavorando ad un decalogo per il paziente ed altri operatori sanitari.

GESPAM: Nel merito, sono in corso, o programmati, collegamenti con altre realtà  operative nazionali o internazionali?

Jean-Louis Aillon: A livello internazionale per ora il campo “€œDecrescita e Salute”€ è praticamente inesplorato, nonostante siano davvero molte le realtà  che lavorano “€œinconsapevolmente”€ in quest’€™ottica. Per ora ci stiamo concentrando sul panorama italiano. Sono numerose ed eterogenee le realtà  che si occupano di questi temi nel contesto italiano e, proprio nell’€™ottica di costruire una rete insieme (ed inoltre dialogare con il mondo della politica), stiamo organizzando con il Movimento per la Decrescita Felice un’€™importante conferenza (1a Conferenza Nazionale Decrescita, Sostenibilità  e Salute: associazioni e politica a confronto) che si terrà  il 28 Ottobre alla Camera dei Deputati (via Campo Marzio 74, aula dei gruppi parlamentari, Roma). Parteciperanno le seguenti associazioni: Cittadinanza Attiva, Associazione Medici per l’Ambiente – ISDE Italia, Centro Salute Internazionale, Università  di Bologna / People’s Health Movement, Medicina Democratica, Slow Food, Osservatorio italiano sulla Salute Globale, Associazione Frantz Fanon, Giù le mani dai bambini, No Grazie pago io, Psichiatria Democratica, Associazione per la Medicina Centrata sulla Persona Onlus, Segretariato Italiano Studenti in Medicina, Andria e la Società  Italiana per la Qualità  nell’Assistenza Sanitaria.

Per  maggiori informazioni potete visitare il seguente link: http://www.eppela.com/ita/projects/541/1a-conferenza-nazionale-decrescita-sostenibilit-e-salute    oppure il nostro sito: http://decrescitafelice.it/

GESPAM: Grazie Dr. Aillon per la disponibilità  ad approfondire con GESPAM queste assolute priorità.

 

————————————————————————-

1 World Health Organization, The Ottawa Charter for Health Promotion, First International Conference on Health Promotion, Ottawa, 21 November 1986

2 Commission on the Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. Geneva: World Health Organization, 2008.

3 Marmot M, Wilkinson R, eds. Social determinants of health: the solid facts. Geneva: World Health Organization, 2003.

4 Declaration of Alma-Ata. International Conference on Primary Health Care, Alma- Ata, USSR, 6–12 September 1978. [Internet]: available at http://www.who.int/hpr/archive/ docs/almaata.html.

5 The World Health Report 2008 – primary Health Care (Now More Than Ever), [internet] available at http://www.who.int/whr/2008/en/index.html

6 Declaration of Alma-Ata. International Conference on Primary Health Care, Alma- Ata, USSR, 6-€“12 September 1978. [Internet] available at: http://www.who.int/hpr/archive/ docs/almaata.html.

7 The World Health Report 2008 – primary Health Care (Now More Than Ever), [internet] available at: http://www.who.int/whr/2008/en/index.html

8 World Health Organization 2002,WHO Traditional Medicine Strategy, 2002-€“2005, Geneva 2002, [internet] available at: http://whqlibdoc.who.int/hq/2002/who_edm_trm_2002.1.pdf

9 World Health Organization ,”Beijing Declaration”, WHO Congress on Traditional Medicine, 7-9 November 2008, Beijing, China, [internet] available at: http://www.who.int/medicines/areas/traditional/congress/beijing_declaration/en/

News Link n. 64

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 64

UNCTAD’s Trade and Environment Review 2013 “Wake up before it is too late: Make agriculture truly sustainable now for food security in a changing climate” 

Italy Calls for Food Security to Be U.N. Priority

Hunger, Food Security, and the African Land Grab

Climate change and land use: Making the difficult choice

IPCC report more certain about global warming

Global warming likely to breach 2C threshold, climate scientists conclude 

UNITED Nations Human rights: Seminar on the right to enjoy the benefits of scientific progress and its applications, 2013 Room XXIV, Palais des Nations, Geneva, 3-4 October 2013

20% of DCI to health & basic education 

28 Ottobre 2013, Camera dei Deputati, Roma:  1a Conferenza Nazionale Decrescita, Sostenibilità e Salute 

Salute e cooperazione internazionale: la FNOMCeO per il volontariato medico e la collaborazione tra istituzioni (Roma, 4-5 ottobre)

Research-based pharmaceutical industry calls for public-private sector engagement to accelerate progress towards the Millennium Development Goals (MDGs) and in planning new development agenda

US Pressure on India Threatens Access to Medicines

Will international development be the undoing of David Cameron?

Why Stephen Harper has no time for the UN

US Ambassador: WIPO Needs More Balance – Toward Rightsholders

WIPO Approves 15 New Observers, Including DNDi, COHRED; Pirate Parties Rejected 

WTO Members Prepare for “Final Countdown” as Ministerial Looms

Visualizing progress on 3 Millennium Development Goals (MDGs)

Analysis: How to tackle slavery in Asia

We Need More Women’s Voices Influencing Our Future Global Goals 

China pledges to aid Thai development

Community consultation published for new ARV guidelines  

Millions of children in India to benefit from IKEA’s €60 million to UNICEF 

How Many Bed Nets Equal a Life Saved? – Why Results Matter for Value for Money 

The Role of Neglected Disease-Endemic, Emerging-Economy Countries in Neglected Disease R&D: Latin America on the Rise

 

 

An ontology of health and sustainable health regions

It is questionable if there has ever been made an attempt to use diplomatic acting, to steer the EU towards a European regional framework.  A framework which should only be based on  politics  used to enforce communicative social systems of networks, and  on indicators of health, well-being and happiness of EU citizens

 An Ontology of Health and Sustainable Health Regions

 

By Tomas Mainil*  

Associate professor, HZ University of Applied Sciences

Capacity group Health, Governance and Transnationalism

From an outside perspective, the EU can seem like several countries or nation states with different goals and different strategies. It is very difficult for the EU commission to govern these states, or act as an interludium.  Historical conflicts have always been embedded within these nation states.  It is questionable if there has ever been made an attempt to use diplomatic acting, to steer the EU towards a European regional framework.  A framework which should only be based on  politics  used to enforce communicative social systems of networks, and  on indicators of health, well-being and happiness of EU citizens.  Power builds at a regional level where regional and city governments have to decide and show vision how to organize  and to govern in such a manner that communities of citizens are still  encouraged to support the political leadership.

What is the solution to mediate the power display of political decision processes?  One possibility is the installment of a framework of sustainable – but also self-regulating health regions in the EU DNA of nation states.  Hypothetically , if France and Germany would be organized   in a similar set of health regions (Mainil, 2013; Botterill, Pennings and Mainil, 2013), the result would be that in the following years, national borders would become less intrusive in citizens’€™ lifes, creating a EU space of health regions, not based on political modes of power, but based on a balance of communicative action and strategic action.

To apply this knowledge to an existing case, we see now that Belgium and the Netherlands are slowly moving towards a joint economic agenda.  Both countries have recently experienced a new king on the throne of their monarchies, which enforces the national identity of their citizens. Both countries have an efficient health system, different in character, but focused on the provision of health care for their own patients.  The quality of their health systems should also enforce the streams of transnational patients to Belgium and the Netherlands, however.  Following some recent articles from the New York Times (Rosenthal, 2013), US citizens are choosing to be treated in Belgium.  The Dutch province of Zeeland is putting efforts to construct itself as a sustainable health region. We have arrived at a momentum in which health and health care systems are challenged on economic and structural efficiency. The next step could be to use health care as an engine to distribute power more equitably, and to enforce sustainable networks of systemic health regions.  One big hurdle are the un-moving movers: medical professionals work in power constellations.  This leads to a strategic confirmation of this group of professionals.  As transnational health care is being developed, new generations of medical doctors have the choice to engage or to confirm.

This rationale towards a dialogical regionalism is currently only a powerless philosophical stance.  Given the need for efficiency and cost budgeting in the national frameworks, however, it could also be seen as a functional tool to formalize governance.  The recently adopted EU Directive on the application of patient rights is a EU initiative to regulate patient mobility.  We argue that the additional governance structure of sustainable health region development could instigate the further development of the existing regulative framework on patient mobility.  The focus of the capacity group Health, Governance and Transnationalism is to assess and test the viability of self-regulating health regions.  The first case studies will be executed in the Netherlands and Belgium.

 

Sources

Mainil, T. (2013). Transnational health care and Medical Tourism: Understanding 21st century patient mobility; towards a rationale of transnational health region development. NRIT Media

Botterill, D., Pennings, G. and Mainil, T. (2013). Medical tourism and Transnational health care. Basingstoke, Palgrave Macmillan.

Rosenthal, E. (2013). In Need of a New Hip, but Priced Out of the U.S. The New York Times, august 3

 

* Dr. Tomas Mainil is Lecturer at Breda University of Applied Sciences (the Netherlands).  He is responsible for the research line ´Transnational health care in sending and receiving contexts´ which was originated at the Centre for cross-cultural Understanding (CCU). He is research fellow at the Research Centre for Longitudinal and Life Course Studies (CELLO), University of Antwerp (Belgium).  He holds an MA in Sociology (Medical Sociology) and a MSc in Quantitative Analysis, and previously worked at the University of Antwerp (department Sociology) and Ghent University (department of General practice and primary health care) on health-related subjects.  His main interests are globalization and health, the policy and governance dynamics of transnational health care (PhD) and the internal and external characteristics  of the transnational health user. 

 

 

News Link n. 63

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 63

Humanitarian futures 

It’s Decision Time in the Fight Against Aids, TB and Malaria

Kapuscinski development lectures series 

More Health for the Money: Putting Incentives to Work for the Global Fund and Its Partners 

Public Engagement in Health Priority Setting in Low- and Middle-Income Countries: Current Trends and Considerations for Policy 

Health Workforce Brain Drain: From Denouncing the Challenge to Solving the Problem

Three Global Health Successes That I Witnessed Firsthand

Grassroots action’ in livestock feeding to help curb global climate change

A Human Rights Approach to Intellectual Property and Access to Medicines

Parliament Member Named IP Adviser To UK Prime Minister

Meeting Highlights Use Of Open Data In Science, Health And Sustainable Development 

Open Knowledge Conference interventions (Geneva, 17-18 September 2013)  

Peruvian Legislators File Motion Seeking Public Debate on the Trans Pacific Partnership 

Chi paga il conto della crisi finanziaria globale?

Africa: Untangling China’s Aid to Africa

Does the Giver Matter? The Human Development Impact of Chinese Aid

Economic development and rural land rights

Building a sustainable foundation for land rights

Why #landmatters for economic development

Does $2,000 save a life? Conditionally, yes  

COOPERAZIONE ITALIANA ALLO SVILUPPO: APPROVATI 57 PROGETTI PROMOSSI DA ONG

A new vaccine in monkeys – could it be the answer to HIV cure?

Experimental leishmaniasis vaccine could overcome challenge of multiple species 

UK pledges £30 million for neglected disease drug R&D

US Congress Members Urge US To Oppose Re-Election Of WIPO Director Gurry 

 

 

 

 

 

 

 

 

News Link n. 62

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 62

G20 leaves developing world behind in tax evasion fight

Hot Topics in the Intellectual Property Chapter of the Trans-Pacific Partnership Agreement (TPP): How Will Things Shake Out?

Trade Ministers, Leaders Give Push To TPP 

Climate makes a discreet comeback on the Brussels agenda

Universal health coverage within reach for developing countries

Global child mortality rates “halved”

PHM Global News, August 2013 

South Centre: Intellectual Property Negotiations Monitor – Issue No. 8, August 2013 

China-Africa Health Cooperation: A New Era?

WHO calls for research for universal health access

Innovative finance can boost global health R&D

WHO Now Charging Fees For Drug Prequalification, Raising Access Fears 

From rhetoric to action: Reaping gains through enhanced women’s land and property rights 

Why we should care about women’s right to land

Recommendations towards an integrated, life-course approach to women’s health in the post-2015 agenda

At the crossroads: transforming health systems to address women’s health across the life course 

Food price fears push EU lawmakers to put a lid on biofuels growth

Oxfam reaction: MEPs’ biofuel compromise is not enough to tackle hunger in poor countries

Biofuels project pushing thousands of people into hunger in Africa

To Feed the World in 2050, We Need to Discuss Agriculture at UN Climate Change Talks 

Growing Share of HIV/AIDS Burden Shifts to Changing Group of Regions 

Survey: 7 out of 8 persons say US residents should not pay more than other high income countries for NIH funded drugs

How to ensure access to good quality, safe and effective medical products in the African Region

‘Strategic Philanthropy’ Shifts Too Much Power to Donors

How realtime evaluation can sharpen our work in fragile states

Will there actually be an aid minister under Abbott?

 

 

 

 

News Link n. 61

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries.

 

News Link 61

Research for universal health coverage: WHO’s World health report 2013 

Questions and answers on Universal Health Coverage…and some more comments and open questions

UNITAID strategy 2013-2016 

DNDi: Connect to fight neglect 

Costi disumani: la spesa pubblica per il “contrasto dell’immigrazione irregolare” 

Why Does the U.S. Need Immigration Reform?

Why We Should Repeal Mandatory Detention of Immigrants

Jim Kim’s ‘science of delivery’: what role for politics?

Change is coming to the World Bank… or is it?

Giving the Poor What They Need, Not Just What We Have

India: Getting Water on Tap in Rural Kerala

Drawing Parallels: Why Drought Persists in Sub-Saharan Africa amidst Arab Springs  

Political will key to ensuring water and sanitation for all, says UN-backed report 

Children pay the price for poverty 

Infographic: Twelve goals to eradicate poverty  

Three Text Messages That Are Changing Africa

Africa will not be Europe’s digital dumping ground, say leaders

Stepping Stones and Creating Futures

Can Brazil Save the United Nations? 

NGO mergers and acquisitions: A growing trend?

Samantha Power: United Nations ‘has lost its way’ 

From relief to digital food: The changing face of humanitarian aid

 Why South Africa’s land reform agenda is stuck

Non-food crops lock up enough calories to feed 4 billion

Focus on Poverty: How can we feed ten billion people?